{"id":25087,"date":"2026-05-07T17:01:35","date_gmt":"2026-05-07T15:01:35","guid":{"rendered":"https:\/\/adragos-pharma.com\/?p=25087"},"modified":"2026-05-08T10:21:23","modified_gmt":"2026-05-08T08:21:23","slug":"sterile-fill-finish-cdmo-audit-checklist","status":"publish","type":"post","link":"https:\/\/adragos-pharma.com\/sterile-fill-finish-cdmo-audit-checklist\/","title":{"rendered":"How to Audit a Sterile Fill-Finish CDMO in 2026"},"content":{"rendered":"<style>\n\/* Adragos Article Styles \u2014 prefixed adr- to prevent theme conflicts *\/<br \/>\n.adr-wrap { font-family: inherit; color: #2d2d2d; line-height: 1.78; max-width: 880px; }<br \/>\n.adr-answer-box { background: #f0f4ff; border-left: 5px solid #1C1C75; padding: 22px 26px; border-radius: 0 8px 8px 0; margin: 0 0 38px; }<br \/>\n.adr-answer-box p { margin: 0; font-size: 1.06em; }<\/p>\n<p>\/* Table of Contents *\/<br \/>\n.adr-toc { background: #ffffff; border: 1px solid #c8d4ff; border-radius: 10px; padding: 26px 30px; margin: 0 0 42px; }<br \/>\n.adr-toc-title { display: flex; align-items: center; gap: 10px; color: #1C1C75; font-size: 0.88em; font-weight: 800; text-transform: uppercase; letter-spacing: 0.09em; margin: 0 0 18px; }<br \/>\n.adr-toc ol { margin: 0; padding-left: 20px; columns: 2; column-gap: 28px; }<br \/>\n.adr-toc li { margin: 7px 0; break-inside: avoid; font-size: 0.93em; }<br \/>\n.adr-toc a { color: #1C1C75; text-decoration: none; font-weight: 500; }<br \/>\n.adr-toc a:hover { color: #8696FE; text-decoration: underline; }<\/p>\n<p>\/* Section structure *\/<br \/>\n.adr-section { margin-top: 52px; }<br \/>\n.adr-section-badge { display: flex; align-items: center; gap: 14px; margin-bottom: 12px; }<br \/>\n.adr-section-badge h2 { margin: 0; color: #1C1C75; font-size: 1.3em; }<br \/>\n.adr-section h2 { color: #1C1C75; font-size: 1.3em; border-bottom: 2px solid #f0f0f0; padding-bottom: 10px; margin-bottom: 16px; }<br \/>\n.adr-num { width: 34px; height: 34px; border-radius: 50%; display: inline-flex; align-items: center; justify-content: center; font-weight: 800; font-size: 0.95em; color: #ffffff; flex-shrink: 0; }<br \/>\n.adr-num-blue { background: #1C1C75; }<br \/>\n.adr-num-purple { background: #8696FE; }<br \/>\n.adr-num-teal { background: #0EC9BB; }<\/p>\n<p>\/* Audit checklist *\/<br \/>\n.adr-checklist { list-style: none; margin: 18px 0; padding: 0; background: #f8f9fc; border-radius: 8px; overflow: hidden; border: 1px solid #eceef3; }<br \/>\n.adr-checklist li { padding: 13px 18px 13px 50px; border-bottom: 1px solid #eceef3; position: relative; font-size: 0.95em; }<br \/>\n.adr-checklist li:last-child { border-bottom: none; }<br \/>\n.adr-checklist li::before { content: \"\u2713\"; position: absolute; left: 17px; top: 13px; color: #0EC9BB; font-weight: 800; font-size: 1.1em; }<\/p>\n<p>\/* Callout boxes *\/<br \/>\n.adr-callout { background: #f0fffb; border: 1px solid #0EC9BB; border-radius: 8px; padding: 18px 22px; margin: 22px 0; }<br \/>\n.adr-callout-label { font-size: 0.76em; font-weight: 800; color: #0EC9BB; text-transform: uppercase; letter-spacing: 0.12em; display: block; margin-bottom: 7px; }<br \/>\n.adr-callout p { margin: 0; font-size: 0.95em; }<br \/>\n.adr-callout a { color: #1C1C75; font-weight: 600; }<\/p>\n<p>\/* Evaluator note *\/<br \/>\n.adr-note { background: #f8f0ff; border-left: 4px solid #8696FE; padding: 15px 20px; margin: 22px 0; border-radius: 0 6px 6px 0; font-size: 0.94em; }<br \/>\n.adr-note strong { color: #5c3d99; }<\/p>\n<p>\/* Visual \/ SVG container *\/<br \/>\n.adr-visual { margin: 38px 0; }<br \/>\n.adr-visual-caption { text-align: center; font-size: 0.86em; color: #777; margin-top: 10px; font-style: italic; }<\/p>\n<p>\/* Tables *\/<br \/>\n.adr-table-wrap { overflow-x: auto; margin: 30px 0; }<br \/>\n.adr-table { width: 100%; border-collapse: collapse; font-size: 0.91em; min-width: 580px; }<br \/>\n.adr-table thead th { background: #1C1C75; color: #ffffff; padding: 13px 15px; text-align: left; font-weight: 700; font-size: 0.88em; letter-spacing: 0.02em; }<br \/>\n.adr-table tbody td { padding: 12px 15px; border-bottom: 1px solid #e5e7eb; vertical-align: top; line-height: 1.6; }<br \/>\n.adr-table tbody tr:last-child td { border-bottom: none; }<br \/>\n.adr-table tbody tr:nth-child(even) td { background: #f8f9fc; }<br \/>\n.adr-table caption { text-align: left; font-weight: 700; color: #1C1C75; padding: 0 0 10px; font-size: 0.94em; }<\/p>\n<p>\/* Priority badges *\/<br \/>\n.adr-badge { display: inline-block; padding: 3px 11px; border-radius: 20px; font-size: 0.79em; font-weight: 800; white-space: nowrap; }<br \/>\n.badge-critical { background: #ffe4e4; color: #b00020; }<br \/>\n.badge-high { background: #fff3e0; color: #a04000; }<br \/>\n.badge-medium { background: #e8f5e9; color: #2e7d32; }<\/p>\n<p>\/* FAQ *\/<br \/>\n.adr-faq { margin: 54px 0 36px; }<br \/>\n.adr-faq-heading { color: #1C1C75; font-size: 1.4em; font-weight: 800; border-bottom: 3px solid #0EC9BB; padding-bottom: 12px; margin-bottom: 26px; }<br \/>\n.adr-faq-item { border: 1px solid #e0e4ec; border-radius: 8px; margin-bottom: 14px; overflow: hidden; }<br \/>\n.adr-faq-q { background: #f8f9fc; padding: 18px 22px; font-weight: 700; color: #1C1C75; font-size: 0.97em; margin: 0; border-bottom: 1px solid #e0e4ec; }<br \/>\n.adr-faq-a { padding: 16px 22px; font-size: 0.95em; line-height: 1.78; color: #2d2d2d; margin: 0; }<br \/>\n.adr-faq-a a { color: #1C1C75; font-weight: 600; }<\/p>\n<p>\/* CTA *\/<br \/>\n.adr-cta { background: linear-gradient(135deg, #1C1C75 0%, #2b2baa 100%); color: #ffffff; border-radius: 10px; padding: 42px 46px; margin: 54px 0 36px; text-align: center; }<br \/>\n.adr-cta h2 { color: #ffffff; margin: 0 0 14px; font-size: 1.38em; }<br \/>\n.adr-cta p { color: rgba(255,255,255,0.88); font-size: 1em; margin: 0 0 26px; line-height: 1.7; }<br \/>\n.adr-cta a.adr-btn { display: inline-block; background: #0EC9BB; color: #ffffff; padding: 14px 38px; border-radius: 5px; text-decoration: none; font-weight: 800; font-size: 1em; letter-spacing: 0.02em; }<br \/>\n.adr-cta a.adr-btn:hover { background: #0ab3a6; }<\/p>\n<p>\/* External link indicator *\/<br \/>\n.adr-wrap a[target=\"_blank\"]::after { content: \" \u2197\"; font-size: 0.74em; opacity: 0.65; }<br \/>\n<\/style>\n<div class=\"adr-wrap\">\n<p><!-- ANSWER-FIRST INTRO --><\/p>\n<div class=\"adr-answer-box\">\n<p><strong>To audit a sterile fill-finish Contract Development and Manufacturing Organisation (CDMO) effectively in 2026, assess nine core areas: quality management systems, contamination control strategy, facility and equipment qualification, technology transfer capability, data integrity controls, analytical and stability services, supply chain resilience, regulatory certification status and personnel qualification.<\/strong> This structured evaluation provides the documented basis required for supplier qualification records, technical quality agreements and your own Chemistry, Manufacturing and Controls regulatory submissions.<\/p>\n<\/div>\n<p><!-- TABLE OF CONTENTS --><\/p>\n<nav class=\"adr-toc\" aria-label=\"Table of Contents\">\n<div class=\"adr-toc-title\">\n<strong>Table of Contents<\/strong><\/div>\n<ol>\n<li><a href=\"#why-2026\">Why Audits Carry Greater Weight in 2026<\/a><\/li>\n<li><a href=\"#pre-audit\">Pre-Audit Documentation<\/a><\/li>\n<li><a href=\"#qms\">1. Quality Management System<\/a><\/li>\n<li><a href=\"#ccs\">2. Contamination Control Strategy<\/a><\/li>\n<li><a href=\"#facility\">3. Facility and Equipment Qualification<\/a><\/li>\n<li><a href=\"#tech-transfer\">4. Technology Transfer Capability<\/a><\/li>\n<li><a href=\"#data-integrity\">5. Data Integrity<\/a><\/li>\n<li><a href=\"#analytical\">6. Analytical Capabilities and Stability<\/a><\/li>\n<li><a href=\"#supply-chain\">7. Supply Chain Resilience<\/a><\/li>\n<li><a href=\"#regulatory\">8. Regulatory Certification<\/a><\/li>\n<li><a href=\"#personnel\">9. Personnel Qualification<\/a><\/li>\n<li><a href=\"#after-audit\">10. After the Audit<\/a><\/li>\n<li><a href=\"#adragos-cluster\">11. Adragos Sterile Cluster Capabilities<\/a><\/li>\n<li><a href=\"#faq\">12. Frequently Asked Questions<\/a><\/li>\n<\/ol>\n<\/nav>\n<p><!-- SVG AUDIT FRAMEWORK VISUAL --><\/p>\n<div class=\"adr-visual\">\n<p style=\"text-align: center; font-weight: 800; color: #1c1c75; font-size: 1.04em; margin-bottom: 16px;\">The Nine-Area Sterile Fill-Finish CDMO Audit Framework<\/p>\n<p>1. Quality Management System<\/p>\n<p>2. Contamination ControlStrategy<\/p>\n<p>3. Facility &amp; Equipment<\/p>\n<p>4. Technology Transfer<\/p>\n<p>5. Data Integrity<\/p>\n<p>6. Analytical &amp; Stability<\/p>\n<p>7. Supply Chain Resilience<\/p>\n<p>8. Regulatory Certification<\/p>\n<p>9. Personnel Qualification<\/p>\n<\/div>\n<p><!-- WHY 2026 --><\/p>\n<section id=\"why-2026\" class=\"adr-section\">\n<h2>Why Sterile Fill-Finish CDMO Audits Carry Greater Weight in 2026<\/h2>\n<p>The 2023 revision of the <a href=\"https:\/\/www.ema.europa.eu\" target=\"_blank\" rel=\"noopener noreferrer\">European Medicines Agency&#8217;s<\/a> Good Manufacturing Practice Annex 1 introduced mandatory Contamination Control Strategy documentation, raising the formal compliance threshold for aseptic processing sites across the sector. At the same time, sterile injectable supply chain disruptions have intensified regulatory and commercial scrutiny of CDMO network depth and manufacturing continuity planning.<\/p>\n<p>For pharmaceutical and biotech quality leaders overseeing sterile injectable CDMO technology transfer and commercial manufacturing partnerships, a poorly structured audit creates material gaps. Those gaps do not simply reside within internal quality logs. They surface during inspections by the European Medicines Agency or the <a href=\"https:\/\/www.fda.gov\" target=\"_blank\" rel=\"noopener noreferrer\">United States Food and Drug Administration<\/a>, and in the most serious cases, during supply events that affect patients directly.<\/p>\n<p>This guide provides a structured framework for quality leaders and clinical supply teams conducting on-site or remote evaluations of sterile fill-finish CDMOs.<\/p>\n<\/section>\n<p><!-- PRE-AUDIT --><\/p>\n<section id=\"pre-audit\" class=\"adr-section\">\n<h2>Before You Begin: Pre-Audit Documentation<\/h2>\n<p>A productive audit begins well before you arrive at the facility. Request the following documentation in advance. Reviewing this package allows on-site time to be directed at genuine risk areas rather than background orientation.<\/p>\n<ul class=\"adr-checklist\">\n<li>Current Good Manufacturing Practice certification documents and a full list of issuing health authorities<\/li>\n<li>The most recent regulatory inspection outcomes and any resulting Corrective Action and Preventive Action documentation<\/li>\n<li>A summary or index of the site&#8217;s Contamination Control Strategy<\/li>\n<li>The current Site Master File or equivalent facility overview document<\/li>\n<li>Technology transfer case studies or capability statements relevant to your target dosage form<\/li>\n<li>Aseptic Process Simulation reports from the most recent manufacturing campaign<\/li>\n<\/ul>\n<\/section>\n<p><!-- AUDIT PRIORITY MATRIX TABLE --><\/p>\n<div class=\"adr-table-wrap\">\n<table class=\"adr-table\" aria-label=\"Sterile fill-finish CDMO audit priority matrix\">\n<caption><strong>Audit Priority Matrix: Risk Level and Key Documentation by Area<\/strong><\/caption>\n<thead>\n<tr>\n<th style=\"text-align: left;\">Audit Area<\/th>\n<th style=\"text-align: left;\">Risk Priority<\/th>\n<th style=\"text-align: left;\">Key Documents to Request<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>Quality Management System<\/strong><\/td>\n<td><span class=\"adr-badge badge-high\">High<\/span><\/td>\n<td>Deviation logs, Corrective Action and Preventive Action records, Annual Product Quality Reviews<\/td>\n<\/tr>\n<tr>\n<td><strong>Contamination Control Strategy<\/strong><\/td>\n<td><span class=\"adr-badge badge-critical\">Critical<\/span><\/td>\n<td>Contamination Control Strategy document, Aseptic Process Simulation reports, environmental monitoring programme<\/td>\n<\/tr>\n<tr>\n<td><strong>Facility and Equipment Qualification<\/strong><\/td>\n<td><span class=\"adr-badge badge-high\">High<\/span><\/td>\n<td>Qualification records, calibration logs, cleaning validation reports<\/td>\n<\/tr>\n<tr>\n<td><strong>Technology Transfer<\/strong><\/td>\n<td><span class=\"adr-badge badge-high\">High<\/span><\/td>\n<td>Transfer protocol templates, process characterisation data, scale-up records<\/td>\n<\/tr>\n<tr>\n<td><strong>Data Integrity<\/strong><\/td>\n<td><span class=\"adr-badge badge-critical\">Critical<\/span><\/td>\n<td>Audit trail review records, data governance standard operating procedures, electronic records management policy<\/td>\n<\/tr>\n<tr>\n<td><strong>Analytical Capabilities and Stability<\/strong><\/td>\n<td><span class=\"adr-badge badge-high\">High<\/span><\/td>\n<td>Method validation reports, International Council for Harmonisation stability study data, out-of-specification investigation logs<\/td>\n<\/tr>\n<tr>\n<td><strong>Supply Chain Resilience<\/strong><\/td>\n<td><span class=\"adr-badge badge-medium\">Medium<\/span><\/td>\n<td>Supplier qualification records, approved supplier lists, business continuity plans<\/td>\n<\/tr>\n<tr>\n<td><strong>Regulatory Certification<\/strong><\/td>\n<td><span class=\"adr-badge badge-critical\">Critical<\/span><\/td>\n<td>Current Good Manufacturing Practice certificates, inspection outcome letters, remediation records<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;\"><strong>Personnel Qualification<\/strong><\/td>\n<td style=\"text-align: left;\"><span class=\"adr-badge badge-medium\">Medium<\/span><\/td>\n<td style=\"text-align: left;\">Training records, aseptic operator gowning qualification data, organisational structure charts<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p><!-- SECTION 1: QMS --><\/p>\n<section id=\"qms\" class=\"adr-section\">\n<div class=\"adr-section-badge\">\n<h2>Quality Management System<\/h2>\n<\/div>\n<p>The quality management system forms the foundation of every other area you will evaluate. A system aligned with the <a href=\"https:\/\/www.ich.org\/page\/quality-guidelines\" target=\"_blank\" rel=\"noopener noreferrer\">International Council for Harmonisation Q10 guideline on Pharmaceutical Quality System<\/a> should be demonstrably operational, not merely documented.<\/p>\n<ul class=\"adr-checklist\">\n<li>Does the site apply a risk-based approach to quality decisions consistent with ICH Q9 on Quality Risk Management?<\/li>\n<li>How are deviations classified, investigated and closed? What does the current open deviation backlog indicate about resolution efficiency?<\/li>\n<li>Is the Corrective Action and Preventive Action process substantively linked to root cause analysis, or is it procedurally compliant but practically superficial?<\/li>\n<li>How does the quality management system interface with customer escalation rights and notification obligations?<\/li>\n<li>What is the site&#8217;s completion rate and average cycle time for Annual Product Quality Reviews?<\/li>\n<\/ul>\n<div class=\"adr-note\"><strong>Evaluator&#8217;s note:<\/strong> A mature quality management system surfaces problems early and closes them systematically. A site presenting a consistently low deviation count without demonstrable depth in its investigation processes warrants closer scrutiny, not approval.<\/div>\n<\/section>\n<p><!-- SECTION 2: CCS --><\/p>\n<section id=\"ccs\" class=\"adr-section\">\n<div class=\"adr-section-badge\">\n<h2>Contamination Control Strategy<\/h2>\n<\/div>\n<p>The Contamination Control Strategy is now one of the most consequential documents a sterile fill-finish site must maintain. Mandated under the revised EMA Annex 1 (2023), a robust strategy must be holistic, risk-based and subject to formal periodic review. It must address all contamination vectors as an interconnected system, not a collection of standalone procedures.<\/p>\n<ul class=\"adr-checklist\">\n<li>Is the Contamination Control Strategy a living document, reviewed at defined intervals and following relevant events such as deviations or environmental excursions?<\/li>\n<li>Does it address personnel, equipment, utilities, materials, process and environment as interconnected risk factors rather than isolated categories?<\/li>\n<li>How is Restricted Access Barrier System (RABS) or isolator technology validated and re-qualified at defined intervals?<\/li>\n<li>What is the scope and frequency of the environmental monitoring programme, and how are adverse trends investigated and escalated?<\/li>\n<li>How are Aseptic Process Simulations designed, conducted and reviewed? What thresholds trigger a formal process review?<\/li>\n<\/ul>\n<div class=\"adr-callout\"><span class=\"adr-callout-label\">Adragos Context<\/span>Adragos operates RABS technology across its sterile manufacturing cluster, including at <a href=\"https:\/\/www.adragos-pharma.com\" target=\"_blank\" rel=\"noopener noreferrer\">Jura in Switzerland<\/a> and at the Maisons-Alfort and Livron sites in France, supporting both aseptic filling and, at Livron, terminal sterilisation processes. Fully compliant Aseptic Process Simulation services are offered at Maisons-Alfort.<\/p>\n<\/div>\n<\/section>\n<p><!-- SECTION 3: FACILITY --><\/p>\n<section id=\"facility\" class=\"adr-section\">\n<div class=\"adr-section-badge\">\n<h2>Facility and Equipment Qualification<\/h2>\n<\/div>\n<p>The physical infrastructure of a sterile fill-finish site underpins every product manufactured within it. Qualification status must be current, documented and traceable across all critical systems.<\/p>\n<ul class=\"adr-checklist\">\n<li>Are all critical utilities \u2014 Water for Injection, Pure Steam and Compressed Gases \u2014 formally qualified and subject to continuous monitoring?<\/li>\n<li>What is the current qualification status of filling lines, lyophilisers and visual inspection systems?<\/li>\n<li>How does the site manage equipment maintenance intervals in relation to campaign planning and batch scheduling?<\/li>\n<li>Are cleaning validation records available and current for all shared product-contact equipment?<\/li>\n<li>Which container closure formats are currently validated \u2014 vials, prefilled syringes and ampoules \u2014 and how are format changes managed through formal change control?<\/li>\n<\/ul>\n<div class=\"adr-note\"><strong>Capacity planning note:<\/strong> For lyophilised vials in particular, lyophiliser capacity directly governs batch size flexibility. A CDMO offering multiple lyophiliser scales on a single site can accommodate clinical trial material production through to small and medium commercial supply without requiring a full technology transfer to a separate facility.<\/div>\n<div class=\"adr-callout\"><span class=\"adr-callout-label\">Adragos Context<\/span>Adragos Jura operates lyophilisers of 3 m\u00b2 and 9 m\u00b2 capacity, supporting batch sizes up to 74,400 vials. This range accommodates clinical trial material production through to small and medium commercial scale from a single regulated site, removing the need for an inter-site technology transfer during scale-up.<\/p>\n<\/div>\n<\/section>\n<p><!-- SECTION 4: TECH TRANSFER --><\/p>\n<section id=\"tech-transfer\" class=\"adr-section\">\n<div class=\"adr-section-badge\">\n<h2>Technology Transfer Capability<\/h2>\n<\/div>\n<p>Technology transfer is the formalised process through which manufacturing knowledge is relocated from a development or originator environment to the CDMO&#8217;s facility. It is one of the highest-risk phases in any sterile injectable CDMO partnership and warrants specific, targeted audit focus.<\/p>\n<ul class=\"adr-checklist\">\n<li>Does the CDMO maintain a defined technology transfer protocol template, and how are knowledge gaps identified and managed throughout the process?<\/li>\n<li>What documented experience does the site hold in receiving transfers for your specific dosage form: liquid vials, lyophilised vials, prefilled syringes or ampoules?<\/li>\n<li>How does the site approach process characterisation and validation planning at receiving scale?<\/li>\n<li>What are the documented timelines from signed agreement to first Good Manufacturing Practice batch for transfers in your dosage form category?<\/li>\n<li>How are comparability studies and analytical method transfers managed, and who holds responsibility for release testing at each stage?<\/li>\n<\/ul>\n<div class=\"adr-note\"><strong>Clinical-to-commercial scale-up risks:<\/strong> The transition from Phase I or Phase II clinical manufacturing to full commercial-scale production introduces considerable risk when manufacturing platforms differ between development and supply scale. Assess whether the CDMO can maintain a consistent process on a single platform from clinical trial materials through to commercial supply. This continuity materially reduces the Chemistry, Manufacturing and Controls documentation burden for EMA and Food and Drug Administration submissions and avoids comparability studies that might otherwise delay a marketing authorisation application.<\/div>\n<div class=\"adr-callout\"><span class=\"adr-callout-label\">Adragos Context<\/span>Adragos Jura produces approximately 200 clinical batches per year and has supported five successful commercial product launches. The site operates without minimum batch size restrictions and targets a three-month turnaround from order to first Good Manufacturing Practice batch for clinical trial materials, including controlled drug handling. Learn more about <a href=\"https:\/\/www.adragos-pharma.com\" target=\"_blank\" rel=\"noopener noreferrer\">Adragos clinical and commercial manufacturing services<\/a>.<\/p>\n<\/div>\n<\/section>\n<p><!-- SECTION 5: DATA INTEGRITY --><\/p>\n<section id=\"data-integrity\" class=\"adr-section\">\n<div class=\"adr-section-badge\">\n<h2>Data Integrity<\/h2>\n<\/div>\n<p>Data integrity failures remain among the most frequently cited grounds for regulatory enforcement actions against pharmaceutical manufacturers worldwide. For sterile fill-finish operations, where batch record accuracy and environmental monitoring data directly affect patient safety, this area requires rigorous and structured evaluation.<\/p>\n<ul class=\"adr-checklist\">\n<li>Does the site operate a formal data governance framework aligned with ALCOA+ principles: Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring and Available?<\/li>\n<li>How are electronic records backed up, and what audit trail review processes are in operation?<\/li>\n<li>Are documented controls in place to prevent backdating or unauthorised alteration of manufacturing records or environmental monitoring data?<\/li>\n<li>How does the site manage hybrid systems that combine paper records and electronic data capture?<\/li>\n<li>Have any data integrity observations been raised during regulatory inspections at this site within the past five years?<\/li>\n<\/ul>\n<\/section>\n<p><!-- SECTION 6: ANALYTICAL --><\/p>\n<section id=\"analytical\" class=\"adr-section\">\n<div class=\"adr-section-badge\">\n<h2>Analytical Capabilities and Stability Services<\/h2>\n<\/div>\n<p>A CDMO&#8217;s in-house analytical resource directly affects batch release timelines, stability data package completeness and regulatory submission readiness. Understanding the breadth of on-site capability reduces dependency on third-party contract laboratories and the associated method transfer risks.<\/p>\n<ul class=\"adr-checklist\">\n<li>Which release testing methods are performed in-house, and which are outsourced to external contract laboratories?<\/li>\n<li>Does the site perform sterility testing, endotoxin detection, bioburden assessment, container closure integrity testing and appearance inspection internally?<\/li>\n<li>What stability chamber capacity is available and under which International Council for Harmonisation climatic zone conditions?<\/li>\n<li>Does the site have documented experience managing stability data packages for Chemistry, Manufacturing and Controls documentation submitted to the EMA and FDA?<\/li>\n<li>How are out-of-specification results managed, and what is the documented investigation and resolution process?<\/li>\n<\/ul>\n<div class=\"adr-callout\"><span class=\"adr-callout-label\">Adragos Context<\/span>Adragos Jura performs stability studies under ICH long-term conditions and conducts sterility, endotoxin and bioburden suitability testing on-site. The facility also operates High Performance Liquid Chromatography validation capabilities in support of release analytics and analytical method transfer activities.<\/p>\n<\/div>\n<\/section>\n<p><!-- SECTION 7: SUPPLY CHAIN --><\/p>\n<section id=\"supply-chain\" class=\"adr-section\">\n<div class=\"adr-section-badge\">\n<h2>Supply Chain Resilience<\/h2>\n<\/div>\n<p>Sterile injectable supply chain disruptions represent an operational risk that has grown considerably in profile. Raw material shortages, primary packaging allocation constraints and Active Pharmaceutical Ingredient supply events have each affected sterile injectable programmes across the sector. A CDMO&#8217;s supply chain strategy should be explicit, documented and auditable.<\/p>\n<ul class=\"adr-checklist\">\n<li>What is the site&#8217;s supplier qualification process for critical raw materials and primary packaging components?<\/li>\n<li>Does the site maintain approved secondary suppliers for critical excipients and primary packaging materials?<\/li>\n<li>How does the CDMO manage capacity allocation across its customer base during supply-constrained periods?<\/li>\n<li>What minimum lead times apply to primary packaging materials relevant to your target dosage form?<\/li>\n<li>How are supply chain disruptions communicated to customers, and what contractual timelines govern notification obligations?<\/li>\n<\/ul>\n<div class=\"adr-note\"><strong>Network depth:<\/strong> A CDMO operating multiple sterile manufacturing facilities within a coordinated network offers supply resilience that a single-site manufacturer cannot replicate. During your audit, establish whether the organisation can redirect manufacturing to an alternative qualified site and what the associated regulatory notification pathway would entail.<\/div>\n<div class=\"adr-callout\"><span class=\"adr-callout-label\">Adragos Context<\/span>Adragos operates a coordinated sterile manufacturing cluster across Jura in Switzerland, Maisons-Alfort in France and Livron in France, supported by visual inspection and packaging services in Japan through Kawagoe. This multi-site structure provides flexibility across clinical trial material and commercial supply requirements and supports multiple regulatory frameworks simultaneously.<\/p>\n<\/div>\n<\/section>\n<p><!-- SECTION 8: REGULATORY --><\/p>\n<section id=\"regulatory\" class=\"adr-section\">\n<div class=\"adr-section-badge\">\n<h2>Regulatory Certification and Inspection History<\/h2>\n<\/div>\n<p>A CDMO&#8217;s regulatory standing is a matter of public and contractual record. It must be reviewed carefully and systematically before entering a commercial manufacturing partnership.<\/p>\n<ul class=\"adr-checklist\">\n<li>Which health authorities hold current Good Manufacturing Practice certification for this site, and when were those certifications most recently issued or renewed?<\/li>\n<li>Are any warning letters, import alerts or equivalent enforcement actions currently in force against this site?<\/li>\n<li>What was the classification and corrective action outcome of the most recent regulatory inspection?<\/li>\n<li>Does the site hold certifications relevant to your target markets \u2014 such as FDA approval for United States market access, EMA certification for European Union access or Pharmaceuticals and Medical Devices Agency certification for the Japanese market?<\/li>\n<li>How does the CDMO support customers in responding to regulatory authority questions about site-specific manufacturing and analytical data?<\/li>\n<\/ul>\n<div class=\"adr-note\"><strong>Multi-market submissions:<\/strong> For organisations pursuing simultaneous EMA and FDA submissions, confirm that the CDMO&#8217;s Site Master File is current for both frameworks and that the facility has been inspected by the FDA within a timeframe acceptable for your submission strategy. CDMOs with active multi-authority certification materially reduce Chemistry, Manufacturing and Controls complexity for global regulatory filings.<\/div>\n<div class=\"adr-callout\"><span class=\"adr-callout-label\">Adragos Context<\/span>Adragos Jura holds current certification from the EMA, the FDA and Swissmedic. Maisons-Alfort operates under EU-GMP standards and holds certifications from twelve international health authorities. Livron holds EU-GMP certification alongside regulatory approvals from the French National Agency for the Safety of Medicines and Health Products (ANSM), the French National Agency for Veterinary Medicinal Products (ANSES) and the Korean Food and Drug Administration (KFDA).<\/p>\n<\/div>\n<\/section>\n<p><!-- SECTION 9: PERSONNEL --><\/p>\n<section id=\"personnel\" class=\"adr-section\">\n<div class=\"adr-section-badge\">\n<h2>Personnel Qualification and Organisational Stability<\/h2>\n<\/div>\n<p>The technical competence and continuity of the people operating the facility carry as much weight as the equipment and procedures they use. Organisational instability in key roles presents a risk that documentation alone cannot mitigate.<\/p>\n<ul class=\"adr-checklist\">\n<li>What is the site&#8217;s attrition rate for Qualified Persons, aseptic operators and quality management personnel over the past two years?<\/li>\n<li>How are aseptic operators trained and re-qualified, and what is the qualification validity period?<\/li>\n<li>Is gowning qualification performed at defined intervals and documented at individual operator level?<\/li>\n<li>Does the site operate a structured knowledge management process that protects institutional expertise through personnel transitions?<\/li>\n<li>Who serves as the dedicated programme contact for your account, and what escalation pathway exists to technical and quality leadership?<\/li>\n<\/ul>\n<\/section>\n<p><!-- AFTER THE AUDIT --><\/p>\n<section id=\"after-audit\" class=\"adr-section\">\n<h2>After the Audit: Structured Evaluation and Next Steps<\/h2>\n<p>Once the audit is complete, assess findings against a risk-tiered framework:<\/p>\n<ul>\n<li><strong>Critical observations:<\/strong> Findings that represent an immediate patient safety risk or an unresolvable regulatory barrier to supply.<\/li>\n<li><strong>Major observations:<\/strong> Findings that require documented corrective action before a supply commitment can be made.<\/li>\n<li><strong>Minor observations:<\/strong> Findings manageable through ongoing supplier quality agreements and scheduled monitoring.<\/li>\n<\/ul>\n<p>Your completed audit report forms part of the supplier qualification documentation retained on file for regulatory inspection purposes. If you are progressing a sterile injectable CDMO technology transfer and commercial manufacturing agreement, audit findings will directly inform the Technical Quality Agreement scope, change control provisions and the ongoing CDMO oversight programme.<\/p>\n<\/section>\n<p><!-- ADRAGOS STERILE CLUSTER TABLE --><\/p>\n<section id=\"adragos-cluster\" class=\"adr-section\">\n<h2>Adragos Pharma Sterile Cluster: Capabilities at a Glance<\/h2>\n<p>For organisations evaluating a commercial technology transfer to a European CDMO, or seeking integrated Phase I to commercial contract manufacturing services, the following table summarises the sterile manufacturing capabilities across the <a href=\"https:\/\/www.adragos-pharma.com\" target=\"_blank\" rel=\"noopener noreferrer\">Adragos Pharma<\/a> network.<\/p>\n<div class=\"adr-table-wrap\">\n<table class=\"adr-table\" aria-label=\"Adragos sterile cluster facility capabilities comparison\">\n<caption><strong>Adragos Sterile Manufacturing Network \u2014 Key Capabilities by Site<\/strong><\/caption>\n<thead>\n<tr>\n<th style=\"text-align: left;\">Facility<\/th>\n<th style=\"text-align: left;\">Location<\/th>\n<th style=\"text-align: left;\">Dosage Forms<\/th>\n<th style=\"text-align: left;\">Key Technology<\/th>\n<th style=\"text-align: left;\">Capacity<\/th>\n<th style=\"text-align: left;\">Regulatory Certifications<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong>Jura<\/strong><\/td>\n<td>Switzerland<\/td>\n<td>Liquid vials, lyophilised vials<\/td>\n<td>RABS, lyophilisers (3 m\u00b2 and 9 m\u00b2), single-use systems<\/td>\n<td>Up to 74,400 vials per batch; approximately 200 clinical batches per year<\/td>\n<td>EMA, FDA, Swissmedic<\/td>\n<\/tr>\n<tr>\n<td><strong>Maisons-Alfort<\/strong><\/td>\n<td>France<\/td>\n<td>Prefilled syringes, liquid vials, lyophilised vials<\/td>\n<td>RABS, CIP\/SIP, 100% automated inspection at up to 600 units\/min<\/td>\n<td>Up to 540 syringes\/min; 150 million units per year<\/td>\n<td>EU-GMP, 12 international health authorities<\/td>\n<\/tr>\n<tr>\n<td><strong>Livron<\/strong><\/td>\n<td>France<\/td>\n<td>Ampoules, suppositories<\/td>\n<td>RABS (aseptic and terminal sterilisation), optical and pinhole detection<\/td>\n<td>120 million ampoule units per year; formulation batches 30\u20131,500 L<\/td>\n<td>EU-GMP, ANSM, ANSES, KFDA<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;\"><strong>Kawagoe<\/strong><\/td>\n<td style=\"text-align: left;\">Japan<\/td>\n<td style=\"text-align: left;\">Visual inspection and packaging (small molecules and biological products)<\/td>\n<td style=\"text-align: left;\">Manual and automated visual inspection; one of Japan&#8217;s largest cold storage warehouses<\/td>\n<td style=\"text-align: left;\">Large-scale cold storage; controlled drug handling<\/td>\n<td style=\"text-align: left;\">Japanese market regulatory alignment; MHLW\/PMDA framework<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/section>\n<p><!-- CTA --><\/p>\n<div class=\"adr-cta\">\n<h2>Ready to Audit Your Next Sterile Fill-Finish Partner?<\/h2>\n<p>Adragos Pharma&#8217;s sterile manufacturing cluster is structured to support client audits with technical transparency, regulatory depth and a dedicated point of contact at every stage. Adragos Jura hosts approximately twelve client audits per year under concurrent EMA, FDA and Swissmedic certification.<\/p>\n<p><a class=\"adr-btn\" href=\"https:\/\/www.adragos-pharma.com\/contact\" target=\"_blank\" rel=\"noopener noreferrer\">Request a Capability Overview<\/a><\/p>\n<\/div>\n<p><!-- FAQ --><\/p>\n<section id=\"faq\" class=\"adr-faq\">\n<h2 class=\"adr-faq-heading\">Frequently Asked Questions<\/h2>\n<div class=\"adr-faq-item\">\n<h4 class=\"adr-faq-q\">What should I assess when auditing a sterile fill-finish CDMO?<\/h4>\n<p class=\"adr-faq-a\">When auditing a sterile fill-finish Contract Development and Manufacturing Organisation, assess nine core areas: quality management systems, contamination control strategy, facility and equipment qualification, technology transfer capability, data integrity controls, analytical and stability services, supply chain resilience, regulatory certification status and personnel qualification. Each area should be evaluated against documented evidence, not verbal assurances.<\/p>\n<\/div>\n<div class=\"adr-faq-item\">\n<h4 class=\"adr-faq-q\">What documents should I request before auditing a sterile fill-finish CDMO?<\/h4>\n<p class=\"adr-faq-a\">Before auditing a sterile fill-finish CDMO, request current Good Manufacturing Practice certification documents, the most recent regulatory inspection outcomes and any Corrective Action and Preventive Action records, a Contamination Control Strategy summary, the current Site Master File, technology transfer case studies relevant to your target dosage form and Aseptic Process Simulation reports from the most recent manufacturing campaign.<\/p>\n<\/div>\n<div class=\"adr-faq-item\">\n<h4 class=\"adr-faq-q\">What does the EMA Annex 1 (2023) Contamination Control Strategy requirement mean for CDMO audits?<\/h4>\n<p class=\"adr-faq-a\">The 2023 revision of EMA Annex 1 mandates that sterile manufacturing sites maintain a formal, holistic Contamination Control Strategy addressing personnel, equipment, utilities, materials, process and environment as interconnected risk factors. During a CDMO audit, evaluators should confirm this document exists, is subject to periodic review and is directly reflected in the site&#8217;s environmental monitoring programme and Aseptic Process Simulation design. A document that exists only on paper without operational implementation is a material audit finding.<\/p>\n<\/div>\n<div class=\"adr-faq-item\">\n<h4 class=\"adr-faq-q\">Why does clinical to commercial scale-up at a sterile fill-finish CDMO carry regulatory risk?<\/h4>\n<p class=\"adr-faq-a\">Clinical to commercial scale-up carries regulatory risk because a change in manufacturing platform between Phase I or Phase II and commercial production may require comparability studies and updated Chemistry, Manufacturing and Controls documentation in EMA and FDA submissions. Selecting a CDMO that can maintain a consistent manufacturing platform from clinical trial materials through to commercial supply reduces this risk and simplifies the regulatory package considerably.<\/p>\n<\/div>\n<div class=\"adr-faq-item\">\n<h4 class=\"adr-faq-q\">What regulatory certifications should a sterile fill-finish CDMO hold for simultaneous EMA and FDA submissions?<\/h4>\n<p class=\"adr-faq-a\">For simultaneous EMA and FDA submissions, a sterile fill-finish CDMO should hold a current EU-GMP certificate and have undergone a Food and Drug Administration inspection within a timeframe acceptable for your submission strategy. The CDMO&#8217;s Site Master File must be current for both regulatory frameworks. Confirm that the site has been directly inspected by the FDA rather than relying solely on Mutual Recognition Agreement equivalence.<\/p>\n<\/div>\n<div class=\"adr-faq-item\">\n<h4 class=\"adr-faq-q\">How do I assess supply chain resilience when selecting a sterile injectable CDMO?<\/h4>\n<p class=\"adr-faq-a\">To assess supply chain resilience, review the site&#8217;s supplier qualification process for critical raw materials and primary packaging components, confirm whether approved secondary suppliers exist for critical materials, establish how capacity is allocated across the customer base during constrained periods and determine whether the CDMO operates within a multi-site network that could provide an alternative manufacturing source in the event of a site-level disruption.<\/p>\n<\/div>\n<div class=\"adr-faq-item\">\n<h4 class=\"adr-faq-q\">What is the difference between RABS and isolator technology in sterile fill-finish manufacturing?<\/h4>\n<p class=\"adr-faq-a\">Restricted Access Barrier Systems (RABS) and isolators both provide physical separation between operators and the aseptic processing zone, reducing contamination risk compared with conventional open cleanroom environments. Isolators provide a higher level of physical separation. Both technologies must be formally validated and re-qualified at defined intervals, and all intervention procedures must be documented and qualified. Confirming which technology a CDMO operates, and how interventions are controlled, is a key audit step under the revised EMA Annex 1.<\/p>\n<\/div>\n<\/section>\n<\/div>\n<p><!-- \/adr-wrap --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>To audit a sterile fill-finish Contract Development and Manufacturing Organisation (CDMO) effectively in 2026, assess nine core areas: quality management systems, contamination control strategy, facility and equipment qualification, technology transfer capability, data integrity controls, analytical and stability services, supply chain [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":21556,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","inline_featured_image":false,"footnotes":""},"categories":[13],"tags":[],"topics":[285],"locations":[],"experts":[],"class_list":["post-25087","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog","topics-fill-and-finish"],"_links":{"self":[{"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/posts\/25087","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/comments?post=25087"}],"version-history":[{"count":5,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/posts\/25087\/revisions"}],"predecessor-version":[{"id":25095,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/posts\/25087\/revisions\/25095"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/media\/21556"}],"wp:attachment":[{"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/media?parent=25087"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/categories?post=25087"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/tags?post=25087"},{"taxonomy":"topics","embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/topics?post=25087"},{"taxonomy":"locations","embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/locations?post=25087"},{"taxonomy":"experts","embeddable":true,"href":"https:\/\/adragos-pharma.com\/wp-json\/wp\/v2\/experts?post=25087"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}